Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Researchers identify regulatory defect that drives lupus

Researchers at Dana-Farber Cancer Institute in Cambridge, Mass., in collaboration with Jackson Laboratory scientists, have identified a regulatory defect that drives lupus.

4 Feb 2011

Kaiser Permanente receives $3 million CDC grant to continue SEARCH study for childhood diabetes

The Kaiser Permanente Southern California Department of Research & Evaluation has been awarded more than $3 million from the Centers for Disease Control and Prevention to continue the SEARCH for Diabetes in Youth Study for an additional five years to 2015.

4 Feb 2011

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

4 Feb 2011

Consumer Reports Health unveils ratings of nine common screenings for heart disease

Consumer Reports Health unveils Ratings of nine common screenings for heart disease based on systematic review of evidence; some screenings work well while others deemed not worth the risk for healthy individuals

3 Feb 2011

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

An innovative diabetes management concept including structured self-monitoring of blood glucose (SMBG), data visualization, pattern analysis and derived therapy adjustments can significantly reduce HbA1c values, improve glycemic control and enhance patients' quality of life. These are the key findings of the 12-month data from the Structured Testing Protocol (STeP) Study, newly published in Diabetes Care.

2 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

2 Feb 2011

Loyola opens Comprehensive Diabetes Care Clinic in Hickory Hills

Untreated or poorly managed diabetes can cause severe health complications such as kidney failure, blindness, heart disease, stroke and nerve damage. To help diabetic patients more easily care for their condition, Loyola has opened the Comprehensive Diabetes Care Clinic at Loyola Center for Health at Hickory Hills.

1 Feb 2011

“Enjoy your food but eat less”: Latest Dietary guidelines

New federal dietary guidelines, released Monday by the U.S. Department of Agriculture and the Department of Health and Human Services lays down some new rules in healthy eating that include consuming less empty calories, less salt and at least half a plate full of fruits and vegetables a day.

1 Feb 2011

Jiangsu Aosaikang Pharmaceutical to take 5% equity position in Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, today announced that a binding subscription agreement has been executed in relation to share placement with Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“ASK”). The proposed placement is for the issue of 14,334,080 LCT shares at A$0.12 per share, to raise A$1.72m. This represents a 5% equity stake in LCT, the funds to be received by LCT from ASK not later than 4 March 2011.

31 Jan 2011

FDA approves GRALISE Tablets for treatment of PHN

Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.

29 Jan 2011

Both absence of insulin and resistance to insulin are associated with defects in FAS

A key mechanism that appears to contribute to blood vessel damage in people with diabetes has been identified by researchers at Washington University School of Medicine in St. Louis.

28 Jan 2011

PCMD forms 6M research and analysis network to investigate role of virus infection in type 1 diabetes

The Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, is one of 13 academic institutions and businesses across Europe to form a -6m research and analysis network, funded by the EU for a five-year period, which is designed to investigate the possible role of virus infection in the cause of type 1 diabetes.

28 Jan 2011

Patients and spouses experience distress related to diabetes

Older patients with diabetes who are not dealing well with the disease are likely to have symptoms of depression, and spouses of older patients also suffer distress related to diabetes and its management, according to research from Purdue University.

28 Jan 2011

Metanx promotes restoration of lost cutaneous sensation in Diabetic Neuropathy patients

PamLab L.L.C., developer and marketer of Metanx®, announced today that the results of a study to determine if nutritional management with Metanx® improves numbness in the feet of patients with Diabetic Neuropathy (DN) was published in the fourth quarter 2010 issue of Reviews in Neurological Diseases. The study demonstrated that Metanx®, a medical food available by prescription, promotes restoration of lost cutaneous sensation in DN patients.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

Elimination of glucagon action may help convert Type 1 diabetes into non-insulin-dependent disorder

Type 1 diabetes could be converted to an asymptomatic, non-insulin-dependent disorder by eliminating the actions of a specific hormone, new findings by UT Southwestern Medical Center researchers suggest.

27 Jan 2011

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

ChemoCentryx, today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.

26 Jan 2011

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

Diamyd completed screening for US Phase III study in type 1 diabetes. The screening of patients for the US Phase III study, DiaPrevent, was completed, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age had, at the completion of screening, been enrolled in the study and received their first injection of the antigen-based therapy Diamyd® or placebo.

25 Jan 2011

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Merck reports GAAP net income of $861 million for 2010

Researchers identify regulatory defect that drives lupus

Kaiser Permanente receives $3 million CDC grant to continue SEARCH study for childhood diabetes

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Consumer Reports Health unveils ratings of nine common screenings for heart disease

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Loyola opens Comprehensive Diabetes Care Clinic in Hickory Hills

“Enjoy your food but eat less”: Latest Dietary guidelines

Jiangsu Aosaikang Pharmaceutical to take 5% equity position in Living Cell Technologies

FDA approves GRALISE Tablets for treatment of PHN

Both absence of insulin and resistance to insulin are associated with defects in FAS

PCMD forms 6M research and analysis network to investigate role of virus infection in type 1 diabetes

Patients and spouses experience distress related to diabetes

Metanx promotes restoration of lost cutaneous sensation in Diabetic Neuropathy patients

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Elimination of glucagon action may help convert Type 1 diabetes into non-insulin-dependent disorder

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in